榄香烯注射液辅助顺铂方案在非小细胞肺癌术后患者中的疗效及对错配切割修复蛋白表达的影响

doi:10.3969/j.issn.1006-6233.2019.01.018

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1311 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 目的:研究榄香烯注射液辅助顺铂方案在非小细胞肺癌术后患者中的疗效以及对错配切割修复蛋白(ERCC1)表达的影响。方法:选取2013年6月至2016年2月我院收治的肺癌术后患者73例,按照随机数字表法分为观察组(n=40例)与对照组(n=33例),对照组采用顺铂方案进行化疗,观察组在对照组的基础上加榄香烯注射液静脉滴注。观察比较两组患者临床治疗效果、远期生存率情况、ERCC1表达情况以及毒副反应情况。结果:治疗后,观察组患者近期总有效率为80%,对照组患者总有效率为72.7%,两组比较无显著差异(P>0.05)。观察组ERCC1的阳性率为100%(40/40),高表达率为65%(26/40),对照组阳性率为78.8%(26/33),高表达率为24.2%(8/33),两组阳性率和高表达率比较差异均显著(P<0.05)。两组患者均出现胃肠道反应、骨髓抑制、过敏反应及肾功能损害等毒副反应,但观察组的各毒副反应发生率较对照组显著更低[(55%)、(45%)、(2.5%)、(20%)vs(84.8%)、(75.8%)、(9.1)、(45.5%)],两组各毒副反应比较差异显著(P<0.05)。随访2年,观察组总生存率为37.5%,中位生存期为19.5个月,1年生存率为67.5%。对照组总生存率为18.2%,中位生存期为9.2个月,1年生存率为42.4%,两组生存率比较差异显著(P<0.05)。结论:在非小细胞肺癌患者术后化疗时辅以榄香烯注射液,能减轻患者毒副反应提高治疗效果,还能降低癌细胞耐药性使错配切割修复蛋白的表达增加。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	张漓
	张靖
	王渊
	谭盼

关键词 ：非小细胞肺癌, 榄香烯, 化疗, 毒副反应, 错配切割修复蛋白

Abstract：Objective: To study the effect of elemene injection assisted cisplatin in patients with non-small cell lung cancer and the effect of mismatch-cleaved repair protein (ERCC1) expression. Methods: 73 patients with postoperative lung cancer admitted to our hospital from June 2013 to February 2016 were randomly divided into observation group (n=40 ) and control group (n=33). The control group received chemotherapy with cisplatin. The observation group was intravenously instilled with elemene injection on the basis of the control group. The clinical treatment effect, long-term survival rate, ERCC1 expression and toxic side effects were observed and compared between the two groups. Results: After treatment, the total effective rate was 80% in the observation group and 72.7% in the control group. There was no significant difference between the two groups (P>0.05). The positive rate of ERCC1 in the observation group was 100% (40/40), the high expression rate was 65% (26/40), the positive rate in the control group was 78.8% (26/33), and the high expression rate was 24.2% (8/33), the positive rate and high expression rate of the two groups were significantly different (P<0.05). Gastrointestinal reactions, myelosuppression, allergic reactions and renal dysfunction were observed in both groups, but the incidence of toxic and side effects in the observation group was significantly lower than that in the control group [(55%), (45%). (2.5%), (20%) vs (84.8%), (75.8%), (9.1), (45.5%)], there were significant differences in toxicity and side effects between the two groups (P<0.05). After 2 years of follow-up, the overall survival rate of the observation group was 37.5%, the median survival time was 19.5 months, and the 1-year survival rate was 67.5%. The overall survival rate of the control group was 18.2%, the median survival time was 9.2 months, and the 1-year survival rate was 42.4%. There was significant difference in survival rate between the two groups (P<0.05). Conclusion: Elemene injection can alleviate the toxicity and side effects of patients with non-small cell lung cancer and improve the therapeutic effect. It can also reduce the drug resistance of cancer cells and increase the expression of mismatch cutting repair protein.

Key words： Non-small cell lung cancer Elemene Chemotherapy Toxic side effects Mismatched repair protein

基金资助:重庆市卫生和计划生育委员会医学科研项目,(编号:20142145);重庆市黔江区科委科技计划项目,(编号:黔科计2016028)

引用本文:

张漓, 张靖, 王渊, 谭盼. 榄香烯注射液辅助顺铂方案在非小细胞肺癌术后患者中的疗效及对错配切割修复蛋白表达的影响[J]. 河北医学, 2019, 25(1): 70-74.
ZHANG Li, ZHANG Jing, WANG Yuan, et al. Efficacy of Elemene Injection Assisted Cisplatin in Patients with Non-small Cell Lung Cancer and Influence on the Expression of Mismatched Repair Proteins. HeBei Med, 2019, 25(1): 70-74.

链接本文:

http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2019.01.018 或 http://www.hbyxzzs.cn/CN/Y2019/V25/I1/70

[1] 李艳,郭其森.晚期非小细胞肺癌维持治疗进展[J].中华肿瘤防治杂志,2014,21(10):800~804.
[2] 宋勇,杨雯.2014年晚期非小细胞肺癌内科治疗进展[J].解放军医学杂志,2015,40(1):10~15.
[3] 郝腾腾,谢雁鸣,廖星,等.参芪扶正注射液联合一线化疗治疗非小细胞肺癌的系统评价及Meta分析[J].中国中药杂志,2015,40(20):4094~4107.
[4] 唐杰,何海浪,许荣龙,等.参芪扶正注射液联合放疗治疗非小细胞肺癌的Meta分析[J].中国实验方剂学杂志,2015,21(1):203~208.
[5] 李培,康晓征,陈克能.ERCC1、RRM1和TS在非小细胞肺癌中的临床意义[J].中国肺癌杂志,2014,17(6):496~500.
[6] Srdic D , Plestina S , Sverko-Peternac A , et al. Cancer cachexia, sarcopenia and biochemical markers in patients with advanced non-small cell lung cancer-chemotherapy toxicity and prognostic value[J]. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2016, 24 (11):4495~502.
[7] Noonan K , Tong KM , Laskin J , et al. Evaluation of a 'watch and wait' approach for chemotherapy in patients with newly diagnosed advanced non-small cell lung cancer from a diverse community population[J]. Clinical oncology (Royal College of Radiologists (Great Britain), 2015, 27 (9):505~13.
[8] Zhou C , Liu D , Li J , et al. Chemotherapy plus dendritic cells co-cultured with cytokine-induced killer cells versus chemotherapy alone to treat advanced non-small-cell lung cancer: A meta-analysis[J]. Oncotarget,2016, 7 (52):86500~86510.
[9] 任维维,米登海,李征,等.非小细胞肺癌紫杉醇类联合顺铂同步或序贯放化疗对比的Meta分析[J].中华肿瘤防治杂志,2013,20(5):377~382.
[10] Heller G , Altenberger C , Steiner I , et al. DNA methylation of microRNA-coding genes in non-small-cell lung cancer patients[J]. The Journal of patholog,2018, 245 (4):387~398.
[11] 韩娜,张孟贤,于世英,等.贝伐单抗联合顺铂/培美曲塞治疗非鳞癌性非小细胞肺癌恶性胸腔积液的临床研究[J].华中科技大学学报(医学版),2013,42(5):588~591,604.
[12] Zhang Y , Sun X , Nan N , et al. Elemene inhibits the migration and invasion of 4T1 murine breast cancer cells via heparanase[J]. moLecular medicine reports. 2017, 16 (1):794~800.
[13] Wu Z , Wang T , Zhang Y , et al. Anticancer effects of β-elemene with hyperthermia in lung cancer cells[J]. Experimental and therapeutic medicine, 2017, 13 (6):3153~3157.
[14] 赵晓菲,靳会欣,周延,等.榄香烯注射液联合TP方案治疗晚期非小细胞肺癌疗效观察[J].中国医院药学杂志,2018,38(2):165~168.